Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease
about
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson diseaseDeconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purposeGlucocerebrosidase and Parkinson disease: Recent advancesGlucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell deathViable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synucleinDysregulation of autophagy and mitochondrial function in Parkinson's diseaseMitochondrial dysfunction associated with glucocerebrosidase deficiencyUpregulation and axonal transport of synaptotagmin-IV in the direct-pathway medium spiny neurons in hemi-parkinsonian rats induced by dopamine D1 receptor stimulationExploring the Effects of Genetic Variants on Clinical Profiles of Parkinson's Disease Assessed by the Unified Parkinson's Disease Rating Scale and the Hoehn-Yahr StageMitochondrial lipids in neurodegenerationGene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body diseaseLIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearanceA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsAffinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluidMacrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.Alpha-synuclein function and dysfunction on cellular membranes.Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.Variants associated with Gaucher disease in multiple system atrophy.Progressive decline of glucocerebrosidase in aging and Parkinson's disease.Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.Gaucher-Associated Parkinsonism.Lysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity.Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.Glucocerebrosidase activity in Parkinson's disease with and without GBA mutationsMannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysisApplications of iPSC-derived models of Gaucher diseaseAcidic Ca2+ stores in neurodegeneration.GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.Age- and brain region-dependent α-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α-synuclein phosphorylation in aging monkey brains.Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity.
P2860
Q22242985-5C3D7F16-529A-41DF-B669-FD49BB43B1A0Q26785491-6872ADDF-0F4E-44C4-A177-C37715192675Q27005669-852D83E7-36A1-4DAE-81C9-9A3566449C83Q27300869-EE14DCAE-74BF-4C3B-B4FA-994AAA4AA3A2Q27311396-2C48187A-599C-4570-B141-B8137B52EAEDQ28071890-CE5CF98D-0820-44B9-8A01-244F4AFDD70BQ28115678-6303A62C-C498-4537-910A-9E4AE71CC820Q28115869-979FE34A-1F6E-44E4-A178-228830B7A6D5Q28396892-17392BA6-1922-499B-AD40-4ED74C1C4094Q28397548-B3FA7994-F6C4-4F73-B14B-7255C7D49970Q28546902-02C04FA3-9666-468E-8F8B-A0DD6621BBBDQ28588670-407851A9-76BD-4348-8080-CF434FB1B3A2Q30235844-11B68DE4-871D-4178-B2ED-0B8AC4619D8AQ30805841-0053B0DA-0F26-4AA9-AC63-E01F795D8AE8Q33831118-B1440975-E649-495B-94C5-A060FE37296AQ34165147-A91338FC-0356-4DE0-BB75-00E781523F8DQ34481921-1D34761F-B52B-4903-9DF9-B9DC404B1E83Q34774324-E9C89878-E206-4F0D-89DC-26D430D980B2Q34964902-ED576322-28C2-4BE2-A225-3E3A23469680Q35152964-6449A594-CD62-4E1C-93FA-A903BD4F8355Q35469633-2BF2F597-6CDA-4F09-958B-366FC80B85F9Q35469684-3DFBE0F2-884F-4CD9-BE05-36D3B6443592Q35596071-B447FC77-EB1E-4217-8377-F11967DF990DQ35851610-D9EB3ED1-787B-4D46-A143-D40CAFFF88A4Q35858682-FABF60A2-9A4A-47BF-8E57-34C49140685AQ35971649-923F056D-1085-41DE-8E1E-147270DFADA8Q35982198-1F139CEC-0C67-4DFF-B925-8462EEA0C9EBQ36041420-665B1A50-B701-4AA3-B312-939D99EE546AQ36100354-97A419B1-F99A-469C-BE21-187CEB4BAA66Q36284241-DE0C28D8-F4A6-4882-BD5A-E45B9F8AFBC3Q36352522-C0E18259-1C88-4E19-9D4A-390B6A41358CQ36395510-0F94E7BA-C77F-4179-8314-0DDD6176DD24Q36777244-27E3D800-2773-452C-B0FA-76D23616DC96Q36962314-856BAADC-2685-47EA-A654-6A405124E30CQ37054024-AC76B90B-696B-46C0-B7AD-87BC2413B93AQ37096051-E0F8601E-0E4C-4F2B-818D-2BBE3A04CBBBQ37120413-A3399778-CB2D-4854-A696-0E7C56467523Q37170658-1216CF1C-6479-4818-857F-DE33D23C7E13Q37189019-0E4FAC43-AA84-474F-A9E9-B328F956A98BQ37443736-28040A06-8DC6-4506-B9AC-716DF04B0F49
P2860
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@ast
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en-gb
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@nl
type
label
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@ast
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en-gb
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@nl
prefLabel
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@ast
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en-gb
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease
@en
P2093
Amanda M Gysbers
Antony Cooper
Brett Garner
Ellen Sidransky
Karen E Murphy
Nahid Tayebi
Sarah K Abbott
Woojin S Kim
P2860
P304
P3181
P356
10.1093/BRAIN/AWT367
P407
P577
2014-03-01T00:00:00Z